Scandion Oncology A/S 14,48
-6,82%
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark. Læs mere
Kr. 499M Markedsværdi
- Omsætning
Bioteknologi Industri
Sverige Hjemland
Sundhed Sektor